FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3094921458> ?p ?o ?g. }

• W3094921458 endingPage "177" @default.
• W3094921458 startingPage "177" @default.
• W3094921458 abstract "<h3>Importance</h3> Reduction of subsequent disabling stroke is the main goal of preventive treatment in the acute setting after transient ischemic attack (TIA) or minor ischemic stroke. <h3>Objective</h3> To evaluate the superiority of ticagrelor added to aspirin in preventing disabling stroke and to understand the factors associated with recurrent disabling stroke. <h3>Design, Setting, and Participants</h3> The Acute Stroke or Transient Ischemic Attack Treated With Ticagrelor and Aspirin for Prevention of Stroke and Death (THALES) was a randomized clinical trial conducted between January 22, 2018, and December 13, 2019, with a 30-day follow-up, at 414 hospitals in 28 countries. The trial included 11 016 patients with a noncardioembolic, nonsevere ischemic stroke or high-risk TIA, including 10 803 with modified Rankin Scale score (mRS) recorded at 30 days. <h3>Interventions</h3> Ticagrelor (180-mg loading dose on day 1 followed by 90 mg twice daily for days 2-30) or placebo within 24 hours of symptom onset. All patients received aspirin, 300 to 325 mg on day 1 followed by 75 to 100 mg daily for days 2 to 30. <h3>Main Outcomes and Measures</h3> Time to the occurrence of disabling stroke (progression of index event or new stroke) or death within 30 days, as measured by mRS at day 30. Disabling stroke was defined by mRS greater than 1. <h3>Results</h3> Among participants with 30-day mRS greater than 1, mean age was 68.1 years, 1098 were female (42.6%), and 2670 had an ischemic stroke (95.8%) as a qualifying event. Among 11 016 patients, a primary end point with mRS greater than 1 at 30 days occurred in 221 of 5511 patients (4.0%) randomized to ticagrelor and in 260 of 5478 patients (4.7%) randomized to placebo (hazard ratio [HR], 0.83; 95% CI, 0.69-0.99,<i>P</i> = .04). A primary end point with mRS 0 or 1 at 30 days occurred in 70 of 5511 patients (1.3%) and 87 of 5478 patients (1.6%) (HR, 0.79; 95% CI, 0.57-1.08;<i>P</i> = .14). The ordinal analysis of mRS in patients with recurrent stroke showed a shift of the disability burden following a recurrent ischemic stroke in favor of ticagrelor (odds ratio, 0.77; 95% CI, 0.65-0.91;<i>P</i> = .002). Factors associated with disability were baseline National Institutes of Health Stroke Scale score 4 to 5, ipsilateral stenosis of at least 30%, Asian race/ethnicity, older age, and higher systolic blood pressure, while treatment with ticagrelor was associated with less disability. <h3>Conclusions and Relevance</h3> In patients with TIA and minor ischemic stroke, ticagrelor added to aspirin was superior to aspirin alone in preventing disabling stroke or death at 30 days and reduced the total burden of disability owing to ischemic stroke recurrence. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT03354429" @default.
• W3094921458 created "2020-11-09" @default.
• W3094921458 creator A5001594817 @default.
• W3094921458 creator A5023091399 @default.
• W3094921458 creator A5046617868 @default.
• W3094921458 creator A5048393176 @default.
• W3094921458 creator A5051592573 @default.
• W3094921458 creator A5065999911 @default.
• W3094921458 creator A5066009203 @default.
• W3094921458 creator A5073596004 @default.
• W3094921458 creator A5079323612 @default.
• W3094921458 creator A5089384391 @default.
• W3094921458 date "2021-02-01" @default.
• W3094921458 modified "2023-10-02" @default.
• W3094921458 title "Ticagrelor Added to Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack in Prevention of Disabling Stroke" @default.
• W3094921458 cites W1480729244 @default.
• W3094921458 cites W1596397105 @default.
• W3094921458 cites W2081615170 @default.
• W3094921458 cites W2129585372 @default.
• W3094921458 cites W2293114504 @default.
• W3094921458 cites W2361921955 @default.
• W3094921458 cites W2399388987 @default.
• W3094921458 cites W2624587018 @default.
• W3094921458 cites W2625474800 @default.
• W3094921458 cites W2726342676 @default.
• W3094921458 cites W2804570339 @default.
• W3094921458 cites W2911427894 @default.
• W3094921458 cites W2956490955 @default.
• W3094921458 cites W2966150926 @default.
• W3094921458 cites W2969448124 @default.
• W3094921458 cites W3001212140 @default.
• W3094921458 cites W3006186234 @default.
• W3094921458 cites W3042274738 @default.
• W3094921458 cites W3043492355 @default.
• W3094921458 doi "https://doi.org/10.1001/jamaneurol.2020.4396" @default.
• W3094921458 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7648910" @default.
• W3094921458 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33159526" @default.
• W3094921458 hasPublicationYear "2021" @default.
• W3094921458 type Work @default.
• W3094921458 sameAs 3094921458 @default.
• W3094921458 citedByCount "19" @default.
• W3094921458 countsByYear W30949214582021 @default.
• W3094921458 countsByYear W30949214582022 @default.
• W3094921458 countsByYear W30949214582023 @default.
• W3094921458 crossrefType "journal-article" @default.
• W3094921458 hasAuthorship W3094921458A5001594817 @default.
• W3094921458 hasAuthorship W3094921458A5023091399 @default.
• W3094921458 hasAuthorship W3094921458A5046617868 @default.
• W3094921458 hasAuthorship W3094921458A5048393176 @default.
• W3094921458 hasAuthorship W3094921458A5051592573 @default.
• W3094921458 hasAuthorship W3094921458A5065999911 @default.
• W3094921458 hasAuthorship W3094921458A5066009203 @default.
• W3094921458 hasAuthorship W3094921458A5073596004 @default.
• W3094921458 hasAuthorship W3094921458A5079323612 @default.
• W3094921458 hasAuthorship W3094921458A5089384391 @default.
• W3094921458 hasBestOaLocation W30949214581 @default.
• W3094921458 hasConcept C126322002 @default.
• W3094921458 hasConcept C127413603 @default.
• W3094921458 hasConcept C142724271 @default.
• W3094921458 hasConcept C164705383 @default.
• W3094921458 hasConcept C204787440 @default.
• W3094921458 hasConcept C27081682 @default.
• W3094921458 hasConcept C2777628954 @default.
• W3094921458 hasConcept C2777849778 @default.
• W3094921458 hasConcept C2780645631 @default.
• W3094921458 hasConcept C2780890252 @default.
• W3094921458 hasConcept C2780931571 @default.
• W3094921458 hasConcept C3020199598 @default.
• W3094921458 hasConcept C42219234 @default.
• W3094921458 hasConcept C541997718 @default.
• W3094921458 hasConcept C71924100 @default.
• W3094921458 hasConcept C78519656 @default.
• W3094921458 hasConceptScore W3094921458C126322002 @default.
• W3094921458 hasConceptScore W3094921458C127413603 @default.
• W3094921458 hasConceptScore W3094921458C142724271 @default.
• W3094921458 hasConceptScore W3094921458C164705383 @default.
• W3094921458 hasConceptScore W3094921458C204787440 @default.
• W3094921458 hasConceptScore W3094921458C27081682 @default.
• W3094921458 hasConceptScore W3094921458C2777628954 @default.
• W3094921458 hasConceptScore W3094921458C2777849778 @default.
• W3094921458 hasConceptScore W3094921458C2780645631 @default.
• W3094921458 hasConceptScore W3094921458C2780890252 @default.
• W3094921458 hasConceptScore W3094921458C2780931571 @default.
• W3094921458 hasConceptScore W3094921458C3020199598 @default.
• W3094921458 hasConceptScore W3094921458C42219234 @default.
• W3094921458 hasConceptScore W3094921458C541997718 @default.
• W3094921458 hasConceptScore W3094921458C71924100 @default.
• W3094921458 hasConceptScore W3094921458C78519656 @default.
• W3094921458 hasIssue "2" @default.
• W3094921458 hasLocation W30949214581 @default.
• W3094921458 hasLocation W30949214582 @default.
• W3094921458 hasLocation W30949214583 @default.
• W3094921458 hasLocation W30949214584 @default.
• W3094921458 hasLocation W30949214585 @default.
• W3094921458 hasOpenAccess W3094921458 @default.
• W3094921458 hasPrimaryLocation W30949214581 @default.
• W3094921458 hasRelatedWork W1969822008 @default.
• W3094921458 hasRelatedWork W2401017187 @default.

• next